Top Purchase Related
Home
>
Node
>
Subnode

The Bevan factor

Roberts, J.A.

Bmj 304(6830): 844

1992

ISSN/ISBN: 0959-8138
PMID: 1392734
Document Number: 397773

Document emailed within 1 workday
Secure & encrypted payments

Middlemass, W.G.; Dodds, R.B. 1974: Robert Bevan Dodds New Zealand Dental Journal 70(321): 211-212
Osterud, B.; Kasper, C.K.; Lavine, K.K.; Prodanos, C.; Rapaport, S.I. 1981: Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VIi and bovine tissue factor Thrombosis and Haemostasis 45(1): 55-59
Andresen, J.L.; Ehlers, N. 1998: Chemotaxis of human keratocytes is increased by platelet-derived growth factor-BB, epidermal growth factor, transforming growth factor-alpha, acidic fibroblast growth factor, insulin-like growth factor-I, and transforming growth factor-beta Current Eye Research 17(1): 79-87
Almus, F.E.; Rao, L.V.; Rapaport, S.I. 1989: Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells Thrombosis and Haemostasis 62(4): 1067-1073
Rizzino, A.; Kazakoff, P.; Ruff, E.; Kuszynski, C.; Nebelsick, J. 1988: Regulatory effects of cell density on the binding of transforming growth factor beta, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor Cancer Research 48(15): 4266-4271
Brown, E.J.; Joiner, K.A.; Gaither, T.A.; Hammer, C.H.; Frank, M.M. 1983: The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system Journal of Immunology 131(1): 409-415
Sugihara, T.; Saito, H. 1987: Application of a monoclonal antibody against factor XIi (Hageman factor); enzyme-linked immunosorbent assay (ELISA) for factor XIi antigen Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 50(3): 691-695
Contino, P.B.; Andree, H.A.; Nemerson, Y. 1994: Flow dependence of factor X activation by tissue factor-factor VIIa Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society 45(1): 81-90
Váradi, K.; Rosing, J.; Tans, G.; Schwarz, H.P. 1995: Influence of factor V and factor Va on APC-induced cleavage of human factor VIIi Thrombosis and Haemostasis 73(4): 730-731
Ishioka, S.; Saito, T.; Hiyama, K.; Haruta, Y.; Maeda, A.; Hozawa, S.; Inamizu, T.; Yamakido, M. 1996: Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis Sarcoidosis Vasculitis and Diffuse Lung Diseases: Official Journal of Wasog 13(2): 139-145
Pfyffer, M.; Kistler, H.J.; von Felten, A. 1983: Acquired hemophilia a due to factor VIIIC inhibitor: detection of circulating immune complexes containing factor VIIIC but not factor VIIIR Schweizerische Medizinische Wochenschrift 113(40): 1456-1459
Ihle, J.N.; Keller, J.; Oroszlan, S.; Henderson, L.E.; Copeland, T.D.; Fitch, F.; Prystowsky, M.B.; Goldwasser, E.; Schrader, J.W.; Palaszynski, E.; Dy, M.; Lebel, B. 1983: Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity Journal of Immunology 131(1): 282-287
Peschen, M.; Grenz, H.; Grothe, C.; Schöpf, E.; Vanscheidt, W. 1998: Patterns of epidermal growth factor receptor, basic fibroblast growth factor and transforming growth factor-beta3 expression in skin with chronic venous insufficiency European Journal of Dermatology: Ejd 8(5): 334-338
Velleman, S.G.; McFarland, D.C. 1999: Influence of fibroblast growth factor, insulin-like growth factor I, and transforming growth factor beta on satellite cell type i collagen expression and localization during differentiation Cytobios 100(394): 101-110
Abdullah, N.A.; Torres, B.A.; Basu, M.; Johnson, H.M. 1989: Differential effects of epidermal growth factor, transforming growth factor-alpha, and vaccinia virus growth factor in the positive regulation of IFN-gamma production Journal of Immunology 143(1): 113-117
Ionescu, C.; Berindan-Neagoe, I.; Burz, C.; Balacescu, O.; Balacescu, L.; Tudoran, O.; Asztalos, R.; Irimie, A. 2011: The clinical implications of platelet derived growth factor B, vascular endothelial growth factor and basic fibroblast growth factor in colorectal cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 16(2): 274-276
Kara, I.Oguz.; Sahin, B.; Gunesacar, R.; Unsal, C. 2006: Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma Advances in Therapy 23(4): 635-645
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Mazurier, C.; Meyer, D. 1996: Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease--results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH Thrombosis and Haemostasis 76(2): 270-274
Lindhout, T.; Franssen, J.; Willems, G. 1995: Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor Thrombosis and Haemostasis 74(3): 910-915